Búsqueda | Biblioteca Virtual en Salud Fronteriza

1.

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).

Navari, Rudolph M; Le-Rademacher, Jennifer; Smieliauskas, Fabrice; Ruddy, Kathryn J; James Saphner, Thomas; Liu, Heshan; Harlos, Elizabeth; Onitilo, Adedayo A; Giridhar, Karthik; Paul Singh, Preet; Reddy, Pavan S; Chow, Selina; Kruter, Flavio; Raptis, George; Loprinzi, Charles L.

Oncologist ; 28(8): 722-729, 2023 08 03.

Artículo en Inglés | MEDLINE | ID: mdl-37284847

2.

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Rapoport, Bernardo Leon; Herrstedt, Jørn; Snow, Rebecca Clark; Radhakrishnan, Venkatraman; Saito, Mitsue; Navari, Rudolph M; Smit, Teresa.

Support Care Cancer ; 32(1): 36, 2023 Dec 18.

Artículo en Inglés | MEDLINE | ID: mdl-38105286

3.

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.

Schwartzberg, Lee; Navari, Rudolph M; Ruddy, Kathryn J; LeBlanc, Thomas W; Clark-Snow, Rebecca; Wickham, Rita; Kloth, Dwight; Binder, Gary; Bailey, William L; Turini, Marco; Potluri, Ravi; Liu, Xing; Papademetriou, Eros; Roeland, Eric J.

Support Care Cancer ; 31(12): 654, 2023 Oct 25.

Artículo en Inglés | MEDLINE | ID: mdl-37878086

4.

Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.

Navari, Rudolph M; Ruddy, Kathryn J; LeBlanc, Thomas W; Nipp, Ryan; Clark-Snow, Rebecca; Schwartzberg, Lee; Binder, Gary; Bailey, William L; Potluri, Ravi; Schmerold, Luke M; Papademetriou, Eros; Roeland, Eric J.

Oncologist ; 26(4): 325-331, 2021 04.

Artículo en Inglés | MEDLINE | ID: mdl-33289268

5.

Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.

Navari, Rudolph M; Binder, Gary; Bonizzoni, Erminio; Clark-Snow, Rebecca; Olivari, Silvia; Roeland, Eric J.

Future Oncol ; 17(23): 3027-3035, 2021 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-33878896

6.

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.

Chow, Ronald; Chiu, Leonard; Herrstedt, Jørn; Aapro, Matti; Lock, Michael; DeAngelis, Carlo; Navari, Rudolph M.

Support Care Cancer ; 29(8): 4269-4275, 2021 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-33409724

7.

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.

Chow, Ronald; Herrstedt, Jørn; Aapro, Matti; Chiu, Leonard; Lam, Henry; Prsic, Elizabeth; Lock, Michael; DeAngelis, Carlo; Navari, Rudolph M.

Support Care Cancer ; 29(7): 3439-3459, 2021 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-33442782

8.

What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.

Roeland, Eric J; Ruddy, Kathryn J; LeBlanc, Thomas W; Nipp, Ryan D; Binder, Gary; Sebastiani, Silvia; Potluri, Ravi; Schmerold, Luke; Papademetriou, Eros; Schwartzberg, Lee; Navari, Rudolph M.

J Natl Compr Canc Netw ; 18(6): 676-681, 2020 06.

Artículo en Inglés | MEDLINE | ID: mdl-32502985

9.

Nausea and Vomiting in Advanced Cancer.

Navari, Rudolph M.

Curr Treat Options Oncol ; 21(2): 14, 2020 02 05.

Artículo en Inglés | MEDLINE | ID: mdl-32025954

10.

Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.

Navari, Rudolph M; Roeland, Eric J.

Future Oncol ; 16(24): 1863-1872, 2020 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-32543309

11.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J; Liu, Heshan; Powell, Steven F; Bajaj, Madhuri; Dietrich, Leah; Biggs, David; Lafky, Jacqueline M; Loprinzi, Charles L.

N Engl J Med ; 375(2): 134-42, 2016 Jul 14.

Artículo en Inglés | MEDLINE | ID: mdl-27410922

12.

HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.

Navari, Rudolph M.

Future Oncol ; 15(3): 241-255, 2019 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-30304952

13.

Managing Nausea and Vomiting in Patients With Cancer: What Works.

Navari, Rudolph M.

Oncology (Williston Park) ; 32(3): 121-5, 131, 136, 2018 03 15.

Artículo en Inglés | MEDLINE | ID: mdl-29548068

14.

Should palonosetron be a preferred 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Chow, Ronald; Warr, David G; Navari, Rudolph M; Tsao, May; Popovic, Marko; Chiu, Leonard; Milakovic, Milica; Lam, Henry; DeAngelis, Carlo.

Support Care Cancer ; 26(8): 2519-2549, 2018 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-29796708

15.

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.

Chow, Ronald; Navari, Rudolph M; Terry, Bryan; DeAngelis, Carlo; Prsic, Elizabeth Horn.

Support Care Cancer ; 30(2): 1015-1018, 2022 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-34613472

16.

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Einhorn, Lawrence H; Rapoport, Bernardo; Navari, Rudolph M; Herrstedt, Jørn; Brames, Mary J.

Support Care Cancer ; 25(1): 303-308, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27815710

17.

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.

Herrstedt, Jørn; Roila, Fausto; Warr, David; Celio, Luigi; Navari, Rudolph M; Hesketh, Paul J; Chan, Alexandre; Aapro, Matti S.

Support Care Cancer ; 25(1): 277-288, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27443154

18.

5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.

Navari, Rudolph M.

Biochim Biophys Acta ; 1848(10 Pt B): 2738-46, 2015 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-25838122

19.

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.

Chiu, Leonard; Chow, Ronald; Popovic, Marko; Navari, Rudolph M; Shumway, Nathan M; Chiu, Nicholas; Lam, Henry; Milakovic, Milica; Pasetka, Mark; Vuong, Sherlyn; Chow, Edward; DeAngelis, Carlo.

Support Care Cancer ; 24(5): 2381-2392, 2016 May.

Artículo en Inglés | MEDLINE | ID: mdl-26768437

20.

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

Schwartzberg, Lee S; Modiano, Manuel R; Rapoport, Bernardo L; Chasen, Martin R; Gridelli, Cesare; Urban, Laszlo; Poma, Allen; Arora, Sujata; Navari, Rudolph M; Schnadig, Ian D.

Lancet Oncol ; 16(9): 1071-1078, 2015 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-26272768

Biblioteca Virtual en Salud Fronteriza

México - Estados Unidos

Su selección (0)

Formato de exportación:

Exportar:

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.

Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.

Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.

What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.

Nausea and Vomiting in Advanced Cancer.

Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.

Managing Nausea and Vomiting in Patients With Cancer: What Works.

Should palonosetron be a preferred 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.

5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.